Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2020.00271
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Preliminary Safety Data of Preoperative Chemotherapy Plus Trastuzumab, Lapatinib or Both in HER2-positive Operable Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2007English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Therapy Landscape in Patients With Metastatic HER2-Positive Breast Cancer: Data From the PRAEGNANT Real-World Breast Cancer Registry

Cancers
Cancer ResearchOncology
2018English

Lapatinib in Combination With Capecitabine Versus Continued Use of Trastuzumab in Breast Cancer Patients With Trastuzumab-Resistance: A Retrospective Study of a Chinese Population

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Results From the First Multicenter, Open-Label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Clinical Breast Cancer
Cancer ResearchOncology
2019English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy